No Increase in Major Cardiac Events With Testosterone-Replacement Therapy
CHICAGO — Testosterone-replacement therapy was noninferior to placebo in the occurrence of major adverse cardiac events among men with hypogonadism and established or high risk for cardiovascular disease, the randomized TRAVERSE trial showed. At a mean follow-up of 33 months, the primary cardiovascular endpoint — first occurrence of any component of a composite of death […]
Platelet-Rich Plasma Injections Flop for Erectile Dysfunction in U.S. Study
CHICAGO — Intracavernosal platelet-rich plasma (PRP) injections were no better than placebo for treating mild-to-moderate erectile dysfunction, a randomized, single-center trial found. At 1 month after the second round of injections, no significant difference was seen between the PRP and placebo groups for the study’s primary endpoint, the percentage of men attaining a minimum clinically […]
Placebo Responses in Migraine Prevention Trials Tick Upward Over Time
Placebo responses in migraine prevention trials appear to have risen over time, a systematic review and meta-analysis showed. A significant increase in placebo response was seen by publication year in migraine prevention studies that involved oral placebo (rho 0.39, P=0.047) but not in studies with injectable placebo (rho -0.07, P=0.724), reported Stewart Tepper, MD, of […]
Remdesivir Appears Effective in COVID Outpatients, Too
Remdesivir (Veklury) reduced risk of hospitalizations by 87% compared with placebo in outpatients at high risk of progression to severe COVID-19, a researcher said. While the raw numbers were small — two in the remdesivir arm versus 15 in the placebo arm — the remdesivir arm had a significantly lower risk of hospitalization (0.7% vs […]